Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.

Trevena Stock Performance

TRVN opened at $1.69 on Friday. The firm has a market cap of $1.46 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. The firm’s 50-day simple moving average is $1.76 and its 200-day simple moving average is $3.86. Trevena has a twelve month low of $1.13 and a twelve month high of $19.23.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The firm had revenue of $0.28 million for the quarter. As a group, sell-side analysts anticipate that Trevena will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.